Mast Therapeutics (MSTX) Tops Q2 EPS by 1c

Mast Therapeutics (NYSE: MSTX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• RBC Capital Reiterates Outperform Rating on Lyft (LYFT), a post-earnings debrief with CFO
• Pony AI (PONY) Reports Revenue Above Estimates